Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Oct;187(1):124-128.
doi: 10.1111/bjh.16009. Epub 2019 Jun 2.

Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia

Jehane Fadlallah  1   2 , Marc Michel  1 , Etienne Crickx  1 , Nicolas Limal  1 , Nathalie Costedoat  3 , Marion Malphettes  2 , Claire Fieschi  2 , Lionel Galicier  2 , Eric Oksenhendler  2 , Bertrand Godeau  1 , Sylvain Audia  4 , Matthieu Mahévas  1   5
Affiliations
Observational Study

Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia

Jehane Fadlallah et al. Br J Haematol. 2019 Oct.

Abstract

We report the off-label use of bortezomib combined with dexamethasone in eight adults with severe and multi-refractory warm auto-immune haemolytic anaemia (wAIHA). After six cycles of induction therapy, 6 of the 8 patients achieved response (3 complete response, 3 response). Response was obtained after a median of 2 (1-4) cycles. After a median follow-up of 14 (6-36) months, six patients maintained a response (bortezomib/dexamethasone maintenance, n = 4); five patients experienced at least one moderate adverse event, including peripheral neuropathy (n = 2). These results suggest that bortezomib/dexamethasone combination is a promising approach with acceptable toxicity for treating severe refractory wAIHA in adults.

Keywords: auto-immune haemolytic anaemia; bortezomib; refractory.

PubMed Disclaimer

References

    1. Alexander, T., Sarfert, R., Klotsche, J., Kuhl, A.A., Rubbert-Roth, A., Lorenz, H.M., Rech, J., Hoyer, B.F., Cheng, Q., Waka, A., Taddeo, A., Wiesener, M., Schett, G., Burmester, G.R., Radbruch, A., Hiepe, F. & Voll, R.E. (2015) The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Annals of the Rheumatic Diseases, 74, 1474-1478.
    1. Barcellini, W., Fattizzo, B., Zaninoni, A., Radice, T., Nichele, I., Di Bona, E., Lunghi, M., Tassinari, C., Alfinito, F., Ferrari, A., Leporace, A.P., Niscola, P., Carpenedo, M., Boschetti, C., Revelli, N., Villa, M.A., Consonni, D., Scaramucci, L., De Fabritiis, P., Tagariello, G., Gaidano, G., Rodeghiero, F., Cortelezzi, A. & Zanella, A. (2014) Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood, 124, 2930-2936.
    1. Dimopoulos, M.A., Orlowski, R.Z., Facon, T., Sonneveld, P., Anderson, K.C., Beksac, M., Benboubker, L., Roddie, H., Potamianou, A., Couturier, C., Feng, H., Ataman, O., van de Velde, H. & Richardson, P.G. (2015) Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica, 100, 100-106.
    1. Fattizzo, B., Zaninoni, A., Nesa, F., Sciumbata, V.M., Zanella, A., Cortelezzi, A. & Barcellini, W. (2015) Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias. American Journal of Hematology, 90, E149-E151.
    1. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 3071-3076.

Publication types

MeSH terms

LinkOut - more resources